President and CEO

Tomohiro Oiwa

A physician, Tomohiro Ooiwa graduated from the Kyoto University Faculty of Medicine. He initially worked as a dermatologist, mainly treating skin cancer and skin immune diseases. Later, he joined the consulting firm Boston Consulting Group, where he engaged in projects related to market entry strategies, supply chain development, and R&D strategy formulation for pharmaceutical companies, both domestic and international.

Working as a physician, he profoundly realized that two things are equally essential for the advancement of the medical industry and the promotion of people's health: (1) providing the best possible treatment to patients in everyday clinical practice, and (2) bringing innovative treatments, not yet part of standard clinical practice, into the world. At Arktus, he sees his mission as the latter. His goal is to tirelessly work towards realizing innovative medical treatments, starting with the knee joint and eventually extending to a broader range of organs.

External Director

Koichi Nakayama

Professor at the Faculty of Medicine, Saga University. After graduating from Kyushu University Faculty of Medicine, he practiced clinically in orthopedics at Kyushu University while starting research in regenerative medicine. He invented the Kenzan-Method and founded Cyfuse Biomedical. The company was listed on the Tokyo Stock Exchange Growth Market in December 2022.

External Director

Makoto Ikeya

Associate Professor at the Kyoto University Center for iPS Cell Research and Application (CiRA). He completed his doctoral program in the Graduate School of Science at Kyoto University, earning a Ph.D. in Science. He developed methods for inducing mesenchymal stem cells, cartilage cells, and tendon/ligament cells from iPS cells.

External Director

Osami Kono

After working as a researcher in a chemical manufacturing company, he spent 20 years at Nikkei BP as a journalist, covering industries including finance, heavy industry, IT, fintech, healthcare, and biotechnology. While at Nikkei Biotech, he followed the latest technological trends in life sciences such as drug discovery, regenerative medicine, and gene therapy. In April 2016, he joined Kyoto University Innovation Capital. He is also involved in Cuorips inc., a project on iPSC-derived cardiac muscle sheets, and Rege Nephro Co., Ltd., focusing on iPSC-derived renal precursor cells. He graduated from the Faculty of Engineering, Kyoto University, majoring in Polymer Chemistry, and completed his postgraduate studies at the Graduate School of Business Sciences, Tsukuba University.